An evaluation of Droperidol for preventing nausea and vomiting after deep intravenous sedation for ambulatory dental surgery.
Four sets of 25 patients were given either 0, 0.25, 0.50, or 1.00 mg droperidol intravenously during deep intravenous sedation for dental surgery in a nonrandomly assigned, single-blind, prospective clinical trial. The control group experienced a 48% incidence of nausea or vomiting, while each of the experimental groups experienced a significantly lower incidence of nausea or vomiting (P = 0.0026). All nausea or vomiting occurred after the patients were discharged and appeared to be motion-related.
Trapp
L D
LD
D000553:Ambulatory Care; D000766:Anesthesia, Dental / Q000009:adverse effects; D000771:Anesthesia, Intravenous / Q000009:adverse effects; D004329:Droperidol / Q000627:therapeutic use*; D006801:Humans; D009325:Nausea / Q000517:prevention & control*; D014839:Vomiting / Q000517:prevention & control*
D004329:Droperidol